Amgen's PSCK9 shows rare disease potential

Share this article:
Amgen's PSCK9 shows rare disease potential
Amgen's PSCK9 shows rare disease potential

Amgen announced Monday another round of positive results for its experimental human monoclonal antibody evolocumab, part of the close PCSK9 race that includes competitors such as partners Sanofi and Regeneron.

Monday's news focused on the antibody's impact on the rare disease homozygous familial hypercholesterolemia, known as HofH. The genetic disorder causes LCL levels to soar by the age of two. The TESLA trial in this patient population was a two-part Phase II/III study that included adult patients and adolescents under the age of 18.

Amgen said in a statement that the trial showed clinically meaningful and statistically significant drops in LDL-C levels at the 12-week mark.

Pursuit of this rare disease indication is one reason the drug has intrigued analysts who estimated in January—when Amgen released Phase III results of its GAUSS-2 trial—that the drug could reach $1 billion in sales by 2020 were it to launch in 2016.

Analysts forecast at the time sales of around $865 million for Sanofi and Regeneron's experimental contender, alirocumab.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.